Cox proportional hazard regression analysis for OS in patients with stage IIIb AL amyloidosis
| Characteristic . | Univariable . | Multivariable . | ||
|---|---|---|---|---|
| HR (95% CI) . | P value . | HR (95% CI) . | P value . | |
| Sx duration > 6 mo | 1.60 (1.10-2.31) | .01 | 1.92 (1.25-2.98) | .003 |
| Lambda LC isotype | 0.76 (0.47-1.23) | .27 | ||
| dFLC > 350 mg/L | 1.81 (1.26-2.62) | .002 | 1.28 (0.82-1.98) | .28 |
| BMPC ≥ 10% | 1.80 (1.18-2.75) | .006 | 2.06 (1.22-3.46) | .007 |
| BNP > 1200 pg/mL | 1.39 (0.96-2.02) | .08 | ||
| TnI > 0.635 ng/mL | 1.62 (1.09-2.42) | .02 | 1.66 (1.03-2.66) | .04 |
| ALP > 105 IU/L | 1.08 (0.75-1.57) | .68 | ||
| Albumin < 3.6 g/dL | 1.02 (0.71-1.46) | .93 | ||
| eGFR < 15 mL per min per 1.73 m2 | 0.86 (0.50-1.49) | .60 | ||
| Proteinuria > 115 mg per 24 h | 1.01 (0.67-1.53) | .95 | ||
| Proteinuria > 5000 mg per 24 h | 0.93 (0.59-1.47) | .77 | ||
| Dialysis | 0.87 (0.46-1.67) | .68 | ||
| Systolic BP < 105 mmHg | 1.09 (0.74-1.60) | .66 | ||
| Diastolic BP < 75 mmHg | 1.00 (0.70-1.44) | .99 | ||
| NYHA class III or IV | 1.65 (0.13-2.41) | .009 | 1.71 (1.06-2.78) | .03 |
| 6MWT < 200 m | 1.72 (1.13-2.63) | .01 | 1.84 (1.16-2.94) | .01 |
| Low voltage | 1.32 (0.92-1.90) | .13 | ||
| Atrial fibrillation/flutter | 1.25 (0.73-2.15) | .42 | ||
| AV blockade | 1.36 (0.88-2.08) | .16 | ||
| RBBB | 1.36 (0.83-2.23) | .23 | ||
| LBBB | 1.23 (0.80-1.89) | .35 | ||
| IVCD | 0.56 (0.20-1.51) | .25 | ||
| PAC | 0.71 (0.35-1.46) | .35 | ||
| PVC | 1.30 (0.73-2.32) | .38 | ||
| IVSd > 15 mm | 1.18 (0.82-1.71) | .38 | ||
| LVIDd > 25 mm | 0.26 (0.04-1.91) | .19 | ||
| LVPWd > 15 mm | 1.09 (0.75-1.59) | .66 | ||
| LVIDs > 32 mm | 0.85 (0.58-1.24) | .41 | ||
| LVEF < 28% | 0.99 (0.52-1.91) | .99 | ||
| Grade 3 diastolic dysfunction | 1.31 (0.90-1.94) | .16 | ||
| LV mass > 276 g | 0.98 (0.64-1.48) | .91 | ||
| LV mass index > 136 g/m2 | 1.11 (0.74-1.66) | .62 | ||
| LV mass index > 153 g/m | 1.09 (0.73-1.64) | .67 | ||
| Bortezomib-based treatment | 0.56 (0.38-0.93) | .003 | 0.44 (0.27-0.70) | <.001 |
| Characteristic . | Univariable . | Multivariable . | ||
|---|---|---|---|---|
| HR (95% CI) . | P value . | HR (95% CI) . | P value . | |
| Sx duration > 6 mo | 1.60 (1.10-2.31) | .01 | 1.92 (1.25-2.98) | .003 |
| Lambda LC isotype | 0.76 (0.47-1.23) | .27 | ||
| dFLC > 350 mg/L | 1.81 (1.26-2.62) | .002 | 1.28 (0.82-1.98) | .28 |
| BMPC ≥ 10% | 1.80 (1.18-2.75) | .006 | 2.06 (1.22-3.46) | .007 |
| BNP > 1200 pg/mL | 1.39 (0.96-2.02) | .08 | ||
| TnI > 0.635 ng/mL | 1.62 (1.09-2.42) | .02 | 1.66 (1.03-2.66) | .04 |
| ALP > 105 IU/L | 1.08 (0.75-1.57) | .68 | ||
| Albumin < 3.6 g/dL | 1.02 (0.71-1.46) | .93 | ||
| eGFR < 15 mL per min per 1.73 m2 | 0.86 (0.50-1.49) | .60 | ||
| Proteinuria > 115 mg per 24 h | 1.01 (0.67-1.53) | .95 | ||
| Proteinuria > 5000 mg per 24 h | 0.93 (0.59-1.47) | .77 | ||
| Dialysis | 0.87 (0.46-1.67) | .68 | ||
| Systolic BP < 105 mmHg | 1.09 (0.74-1.60) | .66 | ||
| Diastolic BP < 75 mmHg | 1.00 (0.70-1.44) | .99 | ||
| NYHA class III or IV | 1.65 (0.13-2.41) | .009 | 1.71 (1.06-2.78) | .03 |
| 6MWT < 200 m | 1.72 (1.13-2.63) | .01 | 1.84 (1.16-2.94) | .01 |
| Low voltage | 1.32 (0.92-1.90) | .13 | ||
| Atrial fibrillation/flutter | 1.25 (0.73-2.15) | .42 | ||
| AV blockade | 1.36 (0.88-2.08) | .16 | ||
| RBBB | 1.36 (0.83-2.23) | .23 | ||
| LBBB | 1.23 (0.80-1.89) | .35 | ||
| IVCD | 0.56 (0.20-1.51) | .25 | ||
| PAC | 0.71 (0.35-1.46) | .35 | ||
| PVC | 1.30 (0.73-2.32) | .38 | ||
| IVSd > 15 mm | 1.18 (0.82-1.71) | .38 | ||
| LVIDd > 25 mm | 0.26 (0.04-1.91) | .19 | ||
| LVPWd > 15 mm | 1.09 (0.75-1.59) | .66 | ||
| LVIDs > 32 mm | 0.85 (0.58-1.24) | .41 | ||
| LVEF < 28% | 0.99 (0.52-1.91) | .99 | ||
| Grade 3 diastolic dysfunction | 1.31 (0.90-1.94) | .16 | ||
| LV mass > 276 g | 0.98 (0.64-1.48) | .91 | ||
| LV mass index > 136 g/m2 | 1.11 (0.74-1.66) | .62 | ||
| LV mass index > 153 g/m | 1.09 (0.73-1.64) | .67 | ||
| Bortezomib-based treatment | 0.56 (0.38-0.93) | .003 | 0.44 (0.27-0.70) | <.001 |
Optimal data cutoff for continuous variables were based on receiver operating characteristic analyses for death at 3 months.
AV, atrioventricular; BP, blood pressure; eGFR, estimated glomerular filtration rate; IVCD, interventricular conduction delay; IVSd, interventricular septum at end diastole; LBBB, left bundle branch block; LVEF, LV ejection fraction; LVIDd, LV internal diameter at end diastole; LVIDs, LV internal diameter at end systole; LVPWd, LV posterior wall at end diastole; PAC, premature atrial contraction; PVC, premature ventricular contraction; RBBB, right bundle branch block; Sx, symptom.